NANBH
MCID: HPT001
MIFTS: 62

Hepatitis C (NANBH)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis C

MalaCards integrated aliases for Hepatitis C:

Name: Hepatitis C 12 75 55 43 44 15 72
Hepatitis C Infection 12 15 17
Hepatitis C, Chronic 72
Chronic Hepatitis C 12
Hepatitis Nona Nonb 12
Hepatitis C Chronic 55
Viral Hepatitis C 12
Nanbh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1883
ICD9CM 35 070.7
MeSH 44 D006526
NCIt 50 C3098
SNOMED-CT 68 50711007
ICD10 33 B19.2 B19.20
UMLS 72 C0019196 C0524910

Summaries for Hepatitis C

MedlinePlus : 43 What is hepatitis C? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. Inflammation can damage organs. There are different types of hepatitis. One type, hepatitis C, is caused by the hepatitis C virus (HCV). Hepatitis C can range from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C can be acute or chronic: Acute hepatitis C is a short-term infection. The symptoms can last up to 6 months. Sometimes your body is able to fight off the infection and the virus goes away. But for most people, an acute infection leads to chronic infection. Chronic hepatitis C is a long-lasting infection. If it is not treated, it can last for a lifetime and cause serious health problems, including liver damage, cirrhosis (scarring of the liver), liver cancer, and even death. How is hepatitis C spread? Hepatitis C spreads through contact with the blood of someone who has HCV. This contact may be through Sharing drug needles or other drug materials with someone who has HCV. In the United States, this is the most common way that people get hepatitis C. Getting an accidental stick with a needle that was used on someone who has HCV. This can happen in health care settings. Being tattooed or pierced with tools or inks that were not sterilized after being used on someone who has HCV Having contact with the blood or open sores of someone who has HCV Sharing personal care items that may have come in contact with another person's blood, such as razors or toothbrushes Being born to a mother with HCV Having unprotected sex with someone who has HCV Before 1992, hepatitis C was also commonly spread through blood transfusions and organ transplants. Since then, there has been routine testing of the U.S. blood supply for HCV. It is now very rare for someone to get HCV this way. Who is at risk for hepatitis C? You are more likely to get hepatitis C if you Have injected drugs Had a blood transfusion or organ transplant before July 1992 Have hemophilia and received clotting factor before 1987 Have been on kidney dialysis Were born between 1945 and 1965 Have abnormal liver tests or liver disease Have been in contact with blood or infected needles at work Have had tattoos or body piercings Have worked or lived in a prison Were born to a mother with hepatitis C Have HIV/AIDS Have had more than one sex partner in the last 6 months Have had a sexually transmitted disease Are a man who has had sex with men If you are at high risk for hepatitis C, your health care provider will likely recommend that you get tested for it. What are the symptoms of hepatitis C? Most people with hepatitis C have no symptoms. Some people with acute hepatitis C do have symptoms within 1 to 3 months after they are exposed to the virus. These symptoms may include Dark yellow urine Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Pain in your abdomen Jaundice (yellowish eyes and skin) If you have chronic hepatitis C, you probably will not have symptoms until it causes complications. This can happen decades after you were infected. For this reason, hepatitis C screening is important, even if you have no symptoms. What are the complications of hepatitis C? Without treatment, hepatitis C may lead to cirrhosis, liver failure, and liver cancer. Early diagnosis and treatment of hepatitis C can prevent these complications. How is hepatitis C diagnosed? Health care providers diagnose hepatitis C based on your medical history, a physical exam, and blood tests. If you do have hepatitis C, you may need additional tests to check for liver damage. These tests may include other blood tests, an ultrasound of the liver, and a liver biopsy. What are the treatments for hepatitis C? Treatment for hepatitis C is with antiviral medicines. They can cure the disease in most cases. If you have acute hepatitis C, your health care provider may wait to see if your infection becomes chronic before starting treatment. If your hepatitis C causes cirrhosis, you should see a doctor who specializes in liver diseases. Treatments for health problems related to cirrhosis include medicines, surgery, and other medical procedures. If your hepatitis C leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis C be prevented? There is no vaccine for hepatitis C. But you can help protect yourself from hepatitis C infection by Not sharing drug needles or other drug materials Wearing gloves if you have to touch another person's blood or open sores Making sure your tattoo artist or body piercer uses sterile tools and unopened ink Not sharing personal items such toothbrushes, razors, or nail clippers Using a condom when you have sex NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis C, also known as hepatitis c infection, is related to hepatitis c virus and viral hepatitis, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis C is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Acarbose and Insulin glulisine have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 75 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1299)
# Related Disease Score Top Affiliating Genes
1 hepatitis c virus 33.9 SCARB1 KRT18 IRF3 IFNL4 IFNG GPT
2 viral hepatitis 33.2 MX1 KRT18 IFNA2 IFNA1 GPT
3 cryoglobulinemia 32.5 IFNA2 CXCL10 CD81
4 cryoglobulinemia, familial mixed 32.4 IFNA2 IFNA1
5 hepatitis a 32.1 MAVS IFNG GPT
6 liver cirrhosis 32.1 KRT18 IFNA1 HOTAIR GPT
7 hepatitis b 31.8 IFNG IFNAR2 IFNA2 IFNA1 GPT
8 acquired immunodeficiency syndrome 31.6 IFNG IFNA2 IFNA1
9 hepatitis 31.5 SCARB1 MAVS KRT18 IRF3 IFNL4 IFNAR2
10 human immunodeficiency virus type 1 31.4 IRF3 IFNG IFNA1 CXCL10
11 west nile virus 31.1 IRF3 IFNA1 DDX58
12 encephalitis 31.1 IRF3 DDX58 CXCL10
13 uveitis 31.1 IFNG IFNA2 CXCL10
14 oral erosive lichen 31.0 IFNB1 IFNA1
15 japanese encephalitis 30.9 IFNB1 DDX58 CXCL10
16 herpes simplex 30.8 IRF3 IFNB1 IFNA1 DDX58
17 kaposi sarcoma 30.7 IRF3 IFNB1 IFNA2 IFNA1
18 rabies 30.6 MX1 IRF3 CXCL10
19 mouth disease 30.4 MX1 IRF3 IFNG IFNA1
20 demyelinating disease 30.4 IFNG IFNB1 IFNA1 CXCL10
21 severe acute respiratory syndrome 30.3 MX1 IRF3 IFNG IFNB1 IFNA1 CXCL10
22 mycosis fungoides 30.3 IFNA2 IFNA1 CXCL10
23 newcastle disease 30.2 IRF3 IFNB1 IFNA1 DDX58
24 multiple sclerosis 30.1 MX1 IFNG IFNB1 IFNA1 CXCL10
25 renal cell carcinoma, nonpapillary 30.1 IFNG IFNA2 IFNA1 HOTAIR
26 influenza 30.1 MX1 IRF3 IFNG IFNB1 IFNA1 DDX58
27 measles 30.1 IFNG IFNB1 IFNAR2 IFNA1 DDX58
28 viral infectious disease 30.0 MX1 MAVS IRF3 IFNG IFNB1 IFNA2
29 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.3
30 hepatocellular carcinoma 11.8
31 liver disease 11.8
32 lichen planus 11.6
33 fatty liver disease 11.6
34 porphyria cutanea tarda 11.6
35 polyarteritis nodosa 11.5
36 opiate dependence 11.5
37 zinc-responsive necrolytic acral erythema 11.5
38 fibrillary glomerulonephritis 11.5
39 intrahepatic cholestasis of pregnancy 11.5
40 immunotactoid glomerulopathy 11.5
41 linear lichen planus 11.5
42 pars planitis 11.5
43 heroin dependence 11.5
44 immunotactoid or fibrillary glomerulopathy 11.5
45 capillariasis 11.2
46 intermediate uveitis 11.2
47 gianotti crosti syndrome 11.2
48 papular mucinosis 11.2
49 vasculitis 10.9
50 glomerulonephritis 10.9

Graphical network of the top 20 diseases related to Hepatitis C:



Diseases related to Hepatitis C

Symptoms & Phenotypes for Hepatitis C

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

Drugs & Therapeutics for Hepatitis C

DrugBank drugs 16 :

(show all 16)
# Drug Name Indication DrugBank ID
1 Asunaprevir Asunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278] Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282] DB11586
2 Boceprevir Boceprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label]. DB08873
3 Daclatasvir Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes. Resistance: Reduced susceptibility to daclatasvir was associated with the polymorphisms at NS5A amino acid positions M28, Q30, L31, and Y93 in genotypes 1a, 1b, and 3a patients. NS5A Resistance Testing is recommended for HCV genotype 1a-infected patients with cirrhosis prior to the initiaition of the treatment, as the risk of resistance development is higher in genotype 1a patients. DB09102
4 Dasabuvir Dasabuvir, in combination with [DB09296], [DB09297], and [DB00503] (as Viekira Pak) is indicated for the treatment of patients with HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] including those with compensated cirrhosis [FDA Label]. DB09183
5 Elbasvir Elbasvir, when used in combination with [DB11575] as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults [FDA Label]. DB11574
6 Glecaprevir Indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [FDA Label]. DB13879
7 Grazoprevir Grazoprevir is indicated in combination with [DB11574] (as the fixed dose combination product Zepatier) with or without [DB00811] for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults. DB11575
8 Interferon alfa-2b For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma. DB00105
9 Ledipasvir When used in combination with the antiviral medication [DB08934] as the commercially available product Harvoni, ledipasvir is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label]. Its use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627]. DB09027
10 Ombitasvir When used in combination with [DB09297] and [DB00503] (as the fixed dose product Technivie), Ombitasvir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis [L866]. When used in combination with [DB09297], [DB00503], and [DB09183] (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with [DB00811], for the treatment of HCV genotype 1a [FDA Label] DB09296
11 Peginterferon alfa-2b Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. DB00022
12 Pibrentasvir Indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [FDA Label]. DB13878
13 Ribavirin Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates [A19644]. The addition of ribavirin in Technivie therapy indicated for treating HCV genotype 1a and 4 infections is recommended in patients with or without cirrhosis. Resistance: viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined. DB00811
14 Simeprevir Indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis. Resistance: Reduced susceptibility to simeprevir was most commonly associated with the viral NS3 Q80K polymorphism. Amino acid substitutions at NS3 positions S122, R155 and/or D168 are also shown to reduce susceptibility to simeprevir in genotype 1a/b patients. DB06290
15 Sofosbuvir Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa. When used in combination with [DB09027] as the combination product Harvoni, sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis. When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis. Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634]. DB08934
16 Velpatasvir Velpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with [DB00811]. When used in combination with [DB08934] as the combination product Epclusa, Velpatasvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis [FDA Label]. DB11613

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 619)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
2
Insulin glulisine Approved Phase 4 207748-29-6
3
Insulin glargine Approved Phase 4 160337-95-1
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
6
Losartan Approved Phase 4 114798-26-4 3961
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
8
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
12
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
13
Citalopram Approved Phase 4 59729-33-8 2771
14
Colchicine Approved Phase 4 64-86-8 6167 2833
15
Infliximab Approved Phase 4 170277-31-3
16
Promethazine Approved, Investigational Phase 4 60-87-7 4927
17
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Didanosine Approved Phase 4 69655-05-6 50599
20
Zidovudine Approved Phase 4 30516-87-1 35370
21
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
22
Fosamprenavir Approved Phase 4 226700-79-4 131536
23
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
24
Nelfinavir Approved Phase 4 159989-64-7 64143
25
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
26
Baclofen Approved Phase 4 1134-47-0 2284
27
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
28
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
29
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
30
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
31
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
32
Insulin Detemir Approved Phase 4 169148-63-4 5311023
33
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
34
Insulin Aspart Approved Phase 4 116094-23-6 16132418
35
Cobicistat Approved Phase 4 1004316-88-4
36
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
37
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
38
Azathioprine Approved Phase 4 446-86-6 2265
39
Topiramate Approved Phase 4 97240-79-4 5284627
40
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
41
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
43
Methadone Approved, Illicit Phase 4 76-99-3 4095
44
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
45
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
46
tannic acid Approved Phase 4 1401-55-4
47
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
48
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
49
Mycophenolic acid Approved Phase 4 24280-93-1 446541
50
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829

Interventional clinical trials:

(show top 50) (show all 2563)
# Name Status NCT ID Phase Drugs
1 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
2 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
3 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
4 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
5 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
6 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
7 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
8 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
9 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
10 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
11 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
12 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
13 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
14 Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4 Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
15 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
16 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
17 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
18 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
19 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
20 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
21 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
22 A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Unknown status NCT03003338 Phase 4 OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
23 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4
24 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
25 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
26 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
27 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
28 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
29 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
30 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
31 The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial Unknown status NCT00841243 Phase 4
32 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
33 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
34 Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
35 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
36 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
37 Safety and Efficacy of Immunosuppression With Basiliximab, Delayed Dose Tacrolimus Plus Enteric Coated Mycophenolic Acid, Versus Standard Dose Tacrolimus, Enteric Coated Mycophenolic Acid Plus Corticosteroids in Patients Undergoing Orthotopic Liver Transplantation (OLT) Unknown status NCT02123108 Phase 4 Basiliximab
38 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
39 Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro) Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
40 Efficacy and Safety of Neutrino Therapy for Chronic HCV Genotype 1b Treatment-experienced Patients Completed NCT02480686 Phase 4 SOF+PEG+RBV
41 Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection Completed NCT02482077 Phase 4 SOF+RBV;SOF+DCV;LDV/SOF
42 Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study Completed NCT02220868 Phase 4 Sofosbuvir, Ribavirin, and Stribild
43 An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes With Patient Demographics and Disease Characteristics in Patients With Chronic Hepatitis C Completed NCT01675427 Phase 4
44 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma Completed NCT00630084 Phase 4 pegylated interferon alpha 2a and plus ribavirin;pegylated interferon alpha 2a and plus ribavirin
45 Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis. Completed NCT00298714 Phase 4 Losartan
46 Efficacy and Safety of Pegylated Interferon Plus Ribavirin Combination Therapy in Treating Older Patients With Chronic Hepatitis C Completed NCT00629824 Phase 4 pegylated interferon alpha and plus ribavirin;pegylated interferon alpha and plus ribavirin;pegylated interferon alpha and plus ribavirin
47 A Prospective, Multicenter, Open-label, Comparative, Efficacy Study of Pegasys® Plus Copegus® in Treatment-naïve Latino Patients With Chronic Hepatitis C-genotype 1, as Compared to Treatment-naïve Non- Latino Caucasian Patients With Chronic Hepatitis C-genotype 1 Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
48 Post-marketing Clinical Trial of Pegasys® 180μg for Subcutaneous Injection in Patients With Chronic Hepatitis C. General Clinical Study in Interferon (IFN)-Treated and IFN-untreated Chronic Hepatitis C Patients, Except for Those Infected With High Viral Load of Genotype 1b Completed NCT00245414 Phase 4 Pegasys®;Pegasys®
49 Comparative Efficacy of Fixed-dose Combination of Sofosbuvir and Ledipasvir for 8 or 12 Weeks for Chronic Hepatitis C Genotype 6 Completed NCT02480166 Phase 4 8 weeks SOF/LED;12 weeks SOF/LED
50 An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C Completed NCT00475072 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Asunaprevir
boceprevir
Boceprevir
daclatasvir
Daclatasvir
dasabuvir
Dasabuvir
elbasvir
Elbasvir
Glecaprevir
grazoprevir
Grazoprevir
Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor [EPC]
Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]
Hepatitis C Virus NS5A Inhibitor [EPC]
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
Interferon Alfa-2a
Interferon alfa-2b
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
ledipasvir
Ledipasvir
ombitasvir
Ombitasvir
paritaprevir
PEGINTERFERON
peginterferon alfa-2a
peginterferon alfa-2b
Peginterferon alfa-2b
Pibrentasvir
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Ribavirin
Ribavirin
simeprevir
Simeprevir
sofosbuvir
Sofosbuvir
telaprevir
velpatasvir
Velpatasvir

Cochrane evidence based reviews: hepatitis c

Genetic Tests for Hepatitis C

Anatomical Context for Hepatitis C

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

19
Liver

MalaCards organs/tissues related to Hepatitis C:

41
Liver, Testes, Kidney, T Cells, B Cells, Thyroid, Bone

Publications for Hepatitis C

Articles related to Hepatitis C:

(show top 50) (show all 32769)
# Title Authors PMID Year
1
Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. 38 88
19122656 2009
2
Influence of the HIV GWG variant in the HIV infection progression in mono and HCV coinfected patients. 17
31335686 2019
3
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. 17
31348267 2019
4
HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics. 17
31305402 2019
5
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. 9 38
20235331 2010
6
Relationship between serum concentrations of keratin-18 and apoptosis in chronic hepatitis C. 9 38
20374042 2010
7
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. 9 38
20169624 2010
8
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. 9 38
20186843 2010
9
R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. 9 38
20090572 2010
10
Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. 9 38
20222873 2010
11
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 9 38
19881359 2010
12
Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies. 9 38
20005287 2010
13
Tissue and serum immune response in chronic hepatitis C with mild histological lesions. 9 38
20209325 2010
14
Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. 9 38
19944069 2010
15
Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. 9 38
19769973 2010
16
[Investigation of the relationship between hepatitis c virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis c patients]. 9 38
20455406 2010
17
Retinol supplements antiviral action of interferon in patients with chronic hepatitis C: a prospective pilot study. 9 38
20104263 2010
18
Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. 9 38
19918044 2010
19
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. 9 38
20203368 2010
20
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. 9 38
19776133 2009
21
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 9 38
20014458 2009
22
Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. 9 38
19586676 2009
23
APRI as a predictor of early viral response in chronic hepatitis C patients. 9 38
19842223 2009
24
Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni co-infection. 9 38
19555400 2009
25
Do statins reduce hepatitis C RNA titers during routine clinical use? 9 38
19859994 2009
26
Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. 9 38
19740312 2009
27
Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. 9 38
19538950 2009
28
[The association of genetic polymorphism of dendritic cell-specific ICAM-grabbing nonintegrin and hepatitis C infection]. 9 38
19785948 2009
29
Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: case study and literature review. 9 38
19855041 2009
30
Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. 9 38
19628164 2009
31
Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. 9 38
19302182 2009
32
Schistosoma mansoni coinfection could have a protective effect against mixed cryoglobulinaemia in hepatitis C patients. 9 38
19192170 2009
33
Human VAP-C negatively regulates hepatitis C virus propagation. 9 38
19515777 2009
34
Antioxidant status and lipid peroxidation activity in evaluating hepatocellular damage in children. 9 38
20187535 2009
35
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. 9 38
19489072 2009
36
Circulating levels of interferon-gamma in course of hepatitis C virus-related arthritis. 9 38
19450146 2009
37
TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. 9 38
19475618 2009
38
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. 9 38
19200135 2009
39
Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. 9 38
19253371 2009
40
Is {beta}-interferon a promising therapeutic option for the management of hepatitis C? 9 38
19329508 2009
41
Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha. 9 38
19238512 2009
42
Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV-infected mothers. 9 38
19228286 2009
43
Serum level of adiponectin correlated with gender and genotype in patients with chronic hepatitis C. 9 38
18773295 2009
44
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry. 9 38
19476617 2009
45
Hepatitis C infection and apoptosis in hepatocellular carcinoma. 9 38
19806812 2009
46
[Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C]. 9 38
19403391 2009
47
Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. 9 38
19480854 2009
48
Serum autoantibodies against cytochrome P450 2E1 (CYP2E1) predict severity of necroinflammation of recurrent hepatitis C. 9 38
19191768 2009
49
Clinical implications of alpha-fetoprotein in chronic hepatitis C. 9 38
19293036 2009
50
Treatment of hepatitis C in liver transplant recipients. 9 38
19177439 2009

Variations for Hepatitis C

Expression for Hepatitis C

Search GEO for disease gene expression data for Hepatitis C.

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 MX1 MAVS IRF3 IFNG IFNB1 IFNAR2
2
Show member pathways
13.22 MX1 IRF3 IFNG IFNB1 IFNAR2 IFNA2
3
Show member pathways
12.9 MAVS IRF3 IFNG IFNB1 IFNAR2 IFNA2
4
Show member pathways
12.89 MX1 IRF3 IFNB1 IFNAR2 IFNA2 IFNA1
5
Show member pathways
12.85 MAVS IRF3 IFNB1 IFNAR2 IFNA2 IFNA1
6 12.42 MAVS IRF3 IFNG IFNA1 DDX58 CXCL10
7
Show member pathways
12.42 MAVS